https://www.selleckchem.com/pr....oducts/caspofungin-a
The treatment landscape for metastatic clear cell renal cell carcinoma (mRCC) is rapidly changing. It is unknown how adoption of new types of therapies may differ by patient age. To compare trends in first-line therapy use for older (≥70 years) and younger ( 7 patients with mRCC before and after approval of nivolumab in 2015. Using the National Cancer Database, we assessed trends in first-line therapy use by calculating the proportion of patients receiving targeted therapy, immunotherapy, or no systemic therapy by year
Like
Comment
Share
